The current status of targeting BAFF/BLyS for autoimmune diseases |
| |
Authors: | Meera Ramanujam Anne Davidson |
| |
Affiliation: | (1) Departments of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA; |
| |
Abstract: | It is increasingly recognized that B cells have multiple functions that contribute to the pathogenesis of autoimmunity. Specific targeting of B cells might therefore be an appropriate therapeutic intervention. The tumor necrosis factor-like molecule BAFF (BLyS) is a key B cell survival factor and its receptors are expressed on most peripheral B cells. Several different BAFF antagonists are under development and in early clinical trials. We review here the rationale for BAFF blockade, and its predicted mechanism of action in autoimmune diseases. |
| |
Keywords: | autoimmune diseases B cells BAFF (BLyS) co-stimulation therapy |
本文献已被 PubMed SpringerLink 等数据库收录! |